651eTiP CAPItana: A phase IIIb study to evaluate the use of capivasertib in combination with fulvestrant in patients with advanced breast cancer who have relapsed/progressed on endocrine therapy and CDK4/6 inhibitors reflecting real-world clinical practice in Spain NCT06764186 | Publicación